Alzamend Neuro Receives Nasdaq Notice Over Equity Deficiency

robot
Abstract generation in progress

Alzamend Neuro (ALZN) received a notice from Nasdaq regarding its stockholders’ equity falling below the required $2.5 million minimum for continued listing on the Nasdaq Capital Market. The company has 45 days to submit a compliance plan and could have up to 180 days to regain compliance. Failure to do so could lead to delisting, although Alzamend Neuro would have the right to appeal.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin